See more : Alpha Teknova, Inc. (TKNO) Income Statement Analysis – Financial Results
Complete financial analysis of Advaxis, Inc. (ADXS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Advaxis, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Minco Silver Corporation (MISVF) Income Statement Analysis – Financial Results
- Scorpex, Inc. (SRPX) Income Statement Analysis – Financial Results
- Fortune Electric Co., Ltd. (1519.TW) Income Statement Analysis – Financial Results
- Tembo Global Industries Limited (TEMBO.NS) Income Statement Analysis – Financial Results
- Yaizu Suisankagaku Industry Co.,Ltd. (2812.T) Income Statement Analysis – Financial Results
Advaxis, Inc. (ADXS)
About Advaxis, Inc.
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.00K | 250.00K | 3.24M | 253.00K | 2.33M | 6.06M | 12.03M | 3.99M | 0.00 | 1.00M | 0.00 | 0.00 | 0.00 | 508.48K | 29.69K | 65.74K | 154.20K | 431.96K | 552.87K | 116.41K | 0.00 | 0.00 |
| Cost of Revenue | 13.00K | 314.00K | 3.71M | 1.29M | 1.29M | 0.00 | 0.00 | 0.00 | 265.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -64.00K | -468.00K | -1.03M | 1.05M | 6.06M | 12.03M | 3.99M | -265.39K | 1.00M | 0.00 | 0.00 | 0.00 | 508.48K | 29.69K | 65.74K | 154.20K | 431.96K | 552.87K | 116.41K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | -25.60% | -14.44% | -407.91% | 44.94% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 24.08M | 7.61M | 10.56M | 15.61M | 14.42M | 56.97M | 71.90M | 48.77M | 24.22M | 8.69M | 5.62M | 6.65M | 8.08M | 4.90M | 2.32M | 2.48M | 2.13M | 1.40M | 1.18M | 125.94K | 0.00 | 0.00 |
| General & Administrative | 12.19M | 9.74M | 11.46M | 11.09M | 4.34M | 19.47M | 38.66M | 31.71M | 24.45M | 11.85M | 9.07M | 5.69M | 4.94M | 3.53M | 2.70M | 3.04M | 2.63M | 2.08M | 1.22M | 524.37K | 10.00K | 10.00K |
| Selling & Marketing | 0.00 | -473.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.19M | 8.42M | 11.46M | 11.09M | 4.34M | 19.47M | 38.66M | 31.71M | 24.45M | 11.85M | 9.07M | 5.69M | 4.94M | 3.53M | 2.70M | 3.04M | 2.63M | 2.08M | 1.22M | 524.37K | 10.00K | 10.00K |
| Other Expenses | 0.00 | 3.05M | -1.00K | -3.00K | 0.00 | -63.00K | -123.00 | -201.00 | -35.08K | 6.24K | -3.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 36.27M | 16.03M | 22.03M | 26.70M | 18.76M | 76.44M | 110.56M | 80.49M | 48.67M | 20.54M | 14.69M | 12.33M | 13.02M | 8.43M | 5.02M | 5.52M | 4.76M | 3.48M | 2.40M | 650.31K | 10.00K | 10.00K |
| Cost & Expenses | 36.28M | 16.34M | 22.03M | 26.70M | 20.05M | 76.44M | 110.56M | 80.49M | 48.67M | 20.54M | 14.69M | 12.33M | 13.02M | 8.43M | 5.02M | 5.52M | 4.76M | 3.48M | 2.40M | 650.31K | 10.00K | 10.00K |
| Interest Income | 28.00K | 74.00K | 5.00K | 110.00K | 225.00K | 577.00K | 669.76K | 331.53K | 114.22K | 36.31K | 5.40K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 15.75M | 0.00 | 260.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.25K | 987.75K | 4.54M | 4.70M | 3.81M | 851.01K | 0.00 | 0.00 | 0.00 | 36.67K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 369.00K | 314.00K | 990.00K | 1.98M | 1.48M | 1.50M | 1.12M | 536.19K | 265.39K | 203.30K | 178.64K | 161.78K | 160.69K | 138.95K | 111.16K | 197.35K | 263.78K | 144.39K | 41.10K | 15.82K | 0.00 | 0.00 |
| EBITDA | -35.87M | -15.78M | -18.77M | -24.39M | -17.56M | -72.28M | -97.43M | -76.03M | -48.36M | -19.29M | -18.04M | -12.17M | -13.78M | -7.79M | -4.88M | -5.30M | -7.09M | -193.70K | -1.80M | -518.14K | -10.00K | -10.00K |
| EBITDA Ratio | -275,915.38% | -6,310.40% | -579.20% | -9,641.90% | -752.40% | -1,192.12% | -809.80% | -1,903.07% | 0.00% | -1,929.27% | 0.00% | 0.00% | 0.00% | -1,531.44% | -16,422.51% | -8,064.18% | -4,601.10% | -44.84% | -325.82% | -445.12% | 0.00% | 0.00% |
| Operating Income | -36.27M | -16.09M | -18.79M | -26.45M | -17.71M | -70.38M | -98.53M | -76.49M | -48.67M | -19.54M | -14.69M | -12.33M | -13.02M | -7.93M | -4.99M | -5.45M | -4.60M | -3.05M | -1.84M | -533.90K | -10.00K | -10.00K |
| Operating Income Ratio | -278,969.23% | -6,436.00% | -579.81% | -10,454.15% | -758.83% | -1,160.79% | -818.95% | -1,914.77% | 0.00% | -1,953.86% | 0.00% | 0.00% | 0.00% | -1,558.76% | -16,796.90% | -8,293.45% | -2,985.06% | -705.91% | -333.25% | -458.66% | 0.00% | 0.00% |
| Total Other Income/Expenses | -16.72M | 1.78M | 974.00K | 30.00K | 225.00K | 3.91M | 20.03K | 68.85K | -84.03K | 625.33K | -5.03M | 4.45M | 10.15M | 649.70K | 5.85M | 46.63K | 2.76M | -2.71M | 36.67K | 57.00 | 0.00 | 0.00 |
| Income Before Tax | -51.98M | -14.31M | -17.81M | -26.42M | -17.49M | -66.47M | -97.84M | -76.09M | -48.64M | -18.88M | -20.71M | -12.42M | -8.50M | -11.09M | 7.22K | -5.41M | -1.85M | -5.76M | -1.81M | -533.85K | -10.00K | -10.00K |
| Income Before Tax Ratio | -399,876.92% | -5,723.60% | -549.75% | -10,442.29% | -749.19% | -1,096.24% | -813.21% | -1,904.75% | 0.00% | -1,888.22% | 0.00% | 0.00% | 0.00% | -2,181.24% | 24.32% | -8,222.52% | -1,197.96% | -1,333.56% | -326.62% | -458.61% | 0.00% | 0.00% |
| Income Tax Expense | -3.91M | 50.00K | 50.00K | 50.00K | 306.00K | 50.00K | -4.40M | -2.54M | -1.61M | -2.36M | -725.19K | -346.79K | -379.47K | -278.98K | -922.02K | -35.37K | -2.15M | 3.15M | -36.67K | 4.17K | 0.00 | 0.00 |
| Net Income | -48.07M | -14.36M | -17.86M | -26.47M | -17.79M | -66.52M | -93.44M | -73.56M | -47.03M | -16.53M | -19.99M | -12.07M | -8.12M | -10.81M | 929.24K | -5.42M | -2.45M | -6.20M | -1.81M | -538.08K | -10.00K | -10.00K |
| Net Income Ratio | -369,784.62% | -5,743.60% | -551.30% | -10,462.06% | -762.30% | -1,097.06% | -776.62% | -1,841.27% | 0.00% | -1,652.53% | 0.00% | 0.00% | 0.00% | -2,126.37% | 3,129.82% | -8,239.65% | -1,591.72% | -1,434.79% | -326.62% | -462.24% | 0.00% | 0.00% |
| EPS | -7.99 | -7.90 | -11.07 | -34.71 | -93.60 | -19.37 | -34.58 | -31.17 | -25.17 | -14.49 | -59.83 | -70.60 | -68.27 | -134.35 | 1.21K | -90.76 | -98.58 | -300.70 | -94.62 | -9.02 | 0.00 | 0.00 |
| EPS Diluted | -7.99 | -7.90 | -11.07 | -34.71 | -93.60 | -19.37 | -34.58 | -31.17 | -25.17 | -14.49 | -59.83 | -70.60 | -68.27 | -134.35 | 1.21K | -90.76 | -98.58 | -300.70 | -94.62 | -9.02 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 6.02M | 1.82M | 1.61M | 762.55K | 190.10K | 3.43M | 2.70M | 2.36M | 1.87M | 1.14M | 334.08K | 170.96K | 118.88K | 80.48K | 61.60K | 59.68K | 24.90K | 20.61K | 19.08K | 59.68K | 145.64M | 145.64M |
| Weighted Avg Shares Out (Dil) | 6.02M | 1.82M | 1.61M | 762.55K | 190.10K | 3.43M | 2.70M | 2.36M | 1.87M | 1.14M | 334.08K | 170.96K | 118.88K | 80.48K | 61.60K | 59.68K | 24.90K | 20.61K | 19.08K | 59.68K | 145.64M | 145.64M |
Top Biotech Penny Stocks to Buy This Week? 9 To Watch
Biotech penny stocks continue to climb, which companies are on your watchlist? The post Top Biotech Penny Stocks to Buy This Week?
ADXS Stock Increases Over 30%: Why It Happened
The stock price of Advaxis, Inc. (NASDAQ: ADXS) increased by over 30% during intraday trading. This is why it happened.
Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today
Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Provention Bio, Inc. (NASDAQ: PRVB) and Advaxis, Inc. (NASDAQ: ADXS) are among the biggest biopharma movers Tuesday. Odonate Gains On Institutional Stake: Shares of Odonate,...
Advaxis and Biosight Announce Entry into Definitive Merger Agreement
– Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program Aspacytarabine (BST-236) in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Advaxis Reports Second Quarter Ended April 30, 2021 Financial Results and Provides a Business Update
ADXS-503 Phase 1/2 trial data presented at ASCO demonstrate disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on KEYTRUDA®
Top Biotech Penny Stocks to Watch in June 2021? Here's 4 For Your List
Biotech penny stocks are pushing up; here's 4 for your watchlist The post Top Biotech Penny Stocks to Watch in June 2021? Here's 4 For Your List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
3 Penny Stocks To Watch Under $2 Making Big Moves Today
Looking for top penny stocks to buy under $2? Check these 3 out for some watchlist inspiration The post 3 Penny Stocks To Watch Under $2 Making Big Moves Today appeared first on Penny Stocks to Buy, Picks, News and...
Advaxis' ADXS-503 Shows Durable Benefit Beyond One Year in Lung Cancer Patients Progressing on Merck's Keytruda
Advaxis Inc (NASDAQ: ADXS) announced updated data from its Phase 1/2 study evaluating ADXS-503 in combination with Merck & Co Inc's Keytruda (pembrolizumab) in patients with metastatic non-small-cell lung cancer (NSCLC). Data will be presented at the American Society of Clinical Oncology 2021...
Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Updated data show disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on pembrolizumab
Biotech Penny Stocks Pushing Up During The Crypto Crash, One Up 25%
Best biotech penny stocks to buy during the crypto crash? Check these 3 out The post Biotech Penny Stocks Pushing Up During The Crypto Crash, One Up 25% appeared first on Penny Stocks to Buy, Picks, News and Information |...
Source: https://incomestatements.info
Category: Stock Reports